KPV 10% OFF This Week | Free Shipping $450+

GLP-3RT and Hepatic Signalling

In cultured primary liver cells (hepatocytes), LY3437943 reduced secretion of ANGPTL3/8, a protein complex involved in lipid metabolism. An antibody that blocked the glucagon receptor prevented the response in the same model. GLP-3RT is Luxara’s catalogue name for material listed as LY3437943.[1]

Key Takeaways

  • GCGR contributed to the secretion response. The receptor-blocking experiment links the observed ANGPTL3/8 change to glucagon receptor activity in that cell model.[1]
  • Glucose output and protein secretion are distinct readouts. The studies measured glucose or ANGPTL3/8 in culture medium using different hepatocyte models.[1] [2]
  • The 2026 mitochondrial study tested glucagon. Its cell experiments provide context for hepatic signalling through GCGR and suggest questions for future LY3437943 research.[4]

What LY3437943 changed in hepatocyte cultures

ANGPTL3/8 secretion

ANGPTL3/8 is a complex of angiopoietin-like proteins 3 and 8 that can inhibit lipoprotein lipase, an enzyme involved in triglyceride hydrolysis. Wen and colleagues measured how much of the complex the cultured hepatocytes released into the medium.[1]

In Figure 3C, secretion with LY3437943 was 45.4% of the control level in the condition without insulin. In Figure 3D it was 50.7% of the control level in the condition with insulin. A GCGR-blocking antibody prevented the reduction in both conditions. Each percentage uses its own control. The study reported 4.6-fold higher secretion with insulin alone. The authors disclosed employment and shareholdings in the compound’s developer.[1]

Glucose output

Coskun and colleagues studied a different response in hepatocytes derived from induced pluripotent stem cells. LY3437943 stimulated glucose output in that assay, which measured glucose in the cell-culture medium. A change in glucose output answers a different question from how the cell stores or oxidizes lipids.[2]

Match each result to its measured endpoint

LY3437943 evidence at the receptor and cell levels
ReadoutWhat the study measured
ANGPTL3/8 secretionProtein complex released by cultured primary hepatocytes. GCGR blockade tested the receptor’s contribution. [1]
Glucose outputGlucose in the medium from stem-cell-derived hepatocytes. [2]
GCGR structureLY3437943 bound to GCGR in a complex with stimulatory G protein. The PDB 8YW5 record reports an overall resolution of 2.84 Å. [3]

For questions about lipid storage or fatty acid oxidation, look for studies that measured those endpoints directly. For a closer look at the receptor contacts and functional assays, see the GLP-3RT Mechanism of Action guide.

2026 pathway evidence from glucagon experiments

Assali and colleagues reported that glucagon increased phosphorylation at Ser258 on NCLX, a mitochondrial sodium–calcium exchanger, in HepG2 cells. In a separate experiment with cultured mouse hepatocytes, loss of NCLX disrupted glucagon-triggered mitochondrial calcium oscillations. Figure 3 links a biochemical change in one cell model to a functional question in another.[4]

These experiments used native glucagon as the stimulus. Testing whether LY3437943 produces the same NCLX response requires measurements with that peptide in the relevant model.[4]

Evidence reviewed through . See Luxara’s research standards and methodology.

Verify the material and its lot documentation

The literature describes the material tested by the investigators. For a Luxara lot, match the label to the corresponding certificate of analysis (COA) in the laboratory results directory. A mass measurement can support identity, chromatographic purity describes the relative signal measured under the test conditions, and a content assay estimates the amount of peptide. The COA reading guide explains how to interpret those measurements. The Luxara Quality Standard describes Luxara’s documentation practices.

For supplier evaluation and lot traceability, see the Canadian peptide sourcing guide.

Frequently asked questions

Which receptor was linked to the ANGPTL3/8 response?

The glucagon receptor, GCGR. A GCGR-blocking antibody prevented the change in ANGPTL3/8 secretion in the primary hepatocyte model.[1]

What do the 45.4% and 50.7% values describe?

They describe ANGPTL3/8 in the culture medium as a percentage of the corresponding control, without and with insulin, respectively. Intracellular lipid storage requires a separate measurement.[1]

Which structure shows LY3437943 at GCGR?

PDB 8YW5 shows LY3437943 bound to GCGR in a complex with stimulatory G protein. The record links to the deposited map and validation report.

Which peptide was tested in the 2026 NCLX experiments?

The cell experiments described here used glucagon. They examined NCLX phosphorylation and mitochondrial calcium signalling in distinct cell models.[4]

Which identifier is used in the primary literature?

Search for LY3437943 to find the original papers and structural records. GLP-3RT is Luxara’s catalogue name.[2] [3]

Sources and structural records

  1. Wen et al. · Diabetes, Obesity and Metabolism · 2025. DOI 10.1111/dom.16661. Primary hepatocyte ANGPTL3/8 experiments, Figure 3.
  2. Coskun et al. · Cell Metabolism · 2022. DOI 10.1016/j.cmet.2022.07.013. Foundational receptor pharmacology and hepatocyte glucose output assay.
  3. Li et al. · Cell Discovery · 2024. DOI 10.1038/s41421-024-00700-0. Receptor cryo-EM structures, including PDB 8YW5.
  4. Assali et al. · Molecular Metabolism · 2026. DOI 10.1016/j.molmet.2026.102433. Glucagon, NCLX phosphorylation and mitochondrial calcium, Figure 3.